-
Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic in advanced HR-positive, HER2-negative breast cancer.
-
The decision makes Guardant360 CDx the first FDA approved liquid biopsy companion diagnostic for longitudinal ctDNA testing in breast cancer care.
-
The approval is supported by clinical trial data where early detection of ESR1 mutations using Guardant360 CDx informed treatment changes for patients.
-
The Guardant360 CDx breast cancer approval is important, but Guardant Health has other moving parts investors should understand in context. We have also flagged
2 warning signs (1 major)for Guardant Health.
For a wider view on how data driven tools are reshaping diagnostics and treatment decisions, explore the broader set of healthcare AI stocks at 37 healthcare AI stocks.
Guardant Health sits in precision oncology, using blood and tissue tests plus large data sets to help clinicians tailor cancer treatment decisions rather than relying only on traditional biopsies. This approval leans on that core model, where recurring liquid biopsies feed molecular data back into real time treatment choices.
2 things going righ...